Valuation: Virbac

Market Cap 2.62B 2.95B 2.45B 2.22B 4.19B 284B 4.22B 29.39B 11.43B 145B 11.06B 10.82B 466B P/E 2026 *
15.1x
P/E 2027 * 13.6x
Enterprise Value 2.74B 3.08B 2.56B 2.32B 4.39B 297B 4.42B 30.77B 11.97B 152B 11.58B 11.33B 488B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.62x
Free-Float
49.03%
Yield 2026 *
0.55%
Yield 2027 * 0.65%
1 day-6.07%
3 months-6.07%
6 months-0.39%
Current year-12.16%
Current year 382.75
Extreme 382.75
413.75
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%-.--% - - 2.95B
+1.26%-2.29%+36.97%+104.79% 1,032B
+0.73%-4.78%+35.41%+61.62% 614B
+0.35%+1.29%+15.86%+79.90% 471B
+1.72%-4.92%+59.84%+36.64% 350B
+1.14%+1.46%+22.77%+41.20% 337B
+1.04%-1.25%+12.65%+34.42% 268B
-0.06%-2.57%-6.38%+10.21% 246B
-0.09%-4.97%+36.88%+50.52% 218B
-0.28%-4.66%+26.99%+92.98% 179B
Average -0.40%-3.39%+26.78%+56.92% 412.76B
Weighted average by Cap. +0.30%-3.18%+29.79%+67.21%

Financials

2026 *2027 *
Net sales 1.55B 1.74B 1.45B 1.31B 2.48B 168B 2.5B 17.39B 6.76B 85.72B 6.54B 6.4B 276B 1.64B 1.85B 1.54B 1.39B 2.63B 179B 2.65B 18.48B 7.19B 91.09B 6.95B 6.8B 293B
Net income 174M 196M 163M 148M 279M 18.88B 281M 1.95B 760M 9.63B 735M 720M 30.97B 194M 218M 181M 164M 310M 21.04B 313M 2.18B 847M 10.73B 819M 802M 34.5B
Net Debt 122M 138M 115M 104M 196M 13.29B 197M 1.38B 535M 6.78B 518M 506M 21.8B 44.72M 50.38M 41.85M 37.93M 71.64M 4.86B 72.15M 503M 195M 2.48B 189M 185M 7.96B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
312.00EUR
Average target price
412.75EUR
Spread / Average Target
+32.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac